GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021 their liquid biopsy, or multi-cancer early detection test was launched, which is called the Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024. Wikipedia